Articles from Investor Brand Network

Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled “Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods,” further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs.

Mullen Automotive (NASDAQMULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups ( https://ibn.fm/Gb5IR ). Other online callouts have noted that Mullen is “making performance EVs to get excited about” ( https://ibn.fm/anGC4 ) and have called Mullen “Tesla’s next potential competitor” ( https://ibn.fm/5Bi4C ).

Lexaria Bioscience (NASDAQLEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.

Cepton (NASDAQCPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, announced the appointment of Paul Anawalt to the newly created position of general counsel, effective today. Anawalt joins Cepton from the Intel Corporation and is a seasoned lawyer with more than 25 years of business and technology law experience, serving as in-house and outside counsel. He has advised public and private companies on strategy, technology transactions, IP, securities, mergers and acquisitions and other areas. “I am grateful for the opportunity to lead the legal organization of Cepton and excited to help strengthen Cepton’s business and develop our legal strategy to support our planned growth,” Anawalt said in the press release. “I look forward to being a part of Cepton’s journey in providing lidar-based solutions for a range of markets.”

Knightscope (NASDAQKSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that its Robot Roadshow will land at the Hollywood Casino in Aurora, Illinois, on April 19-20 from 10:00 a.m. to 2:00 p.m. CT, and at Digby’s Detective & Security Agency in Chicago, Illinois, on April 21, 2022, from 10:00 a.m. to 2:00 p.m. CT. A Knightscope expert virtually attends each Roadshow landing, and visitors will have the opportunity to see the Knightscope Security Operations Center (“KSOC”) user interface in action and interact directly with each of the company’s autonomous security robots.

Shares of GlaxoSmithKline PLC (NYSEGSK) traded at a new 12-month high today of $46.97. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 5.2 million shares.

Shares of Bumble Inc. (NASDAQBMBL) traded today at $84.80, eclipsing its 12-month high. This new high was reached on above average trading volume as 52.5 million shares traded hands, while the average 30-day volume is approximately 4.8 million shares.

Kaival Brands (NASDAQKAVL), the exclusive global distributor of all products made by Bidi(R) Vapor LLC, including the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”), is expanding its distribution by adding both wholesale and retail accounts. Kaival anticipates the new distribution footprint will cover an estimated 28,000 additional stores. The announcement comes after the U.S. Food and Drug Administration issued a marketing denial order (“MDO”) to Bidi Vapor last year, as it did for some 96% of all manufacturers of flavored ENDS. However, earlier this year the U.S. Court of Appeals for the Eleventh Circuit granted Bidi Vapor a judicial stay of the MDO, while the courts determine the result of Bidi Vapor’s ongoing merits-based litigation. “We are encouraged by growing sales volumes in our second fiscal quarter generated by both established wholesalers and retailers selling the BIDI Stick in new stores, as well as new wholesale and retail accounts being added to our distribution network,” said Kaival Brands CEO Niraj Patel in the press release. “We anticipate the activation of approximately 3,900 new store locations over the next 45 days, including one new major retailer having already placed orders totaling more than $1.1 million. . . . The judicial stay granted in February allowed us to resume sale of all 11 flavored products in the BIDI Stick lineup. We are eager to return our flavored products to the shelves of retailers that comply with the Prevent All Cigarette Trafficking Act so adult consumers can enjoy their preferred flavors once again. As a result of the judicial stay, we expect revenues to resume an upward trajectory as renewed distribution ramps up and sales of flavored BIDI Sticks increase.”

InMed Pharmaceuticals (NASDAQINM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the coming months as its next revenue generators…. The company expects to produce more than 100 kilograms of CBDV and THCV under the initiative. Because of the very limited quantities of rare cannabinoids that make them effectively impractical from an economic standpoint to extract directly from the plant for pharmaceutical use, InMed’s R&D operation is working to develop synthetic formulations for the treatment of specific conditions.”

SRAX (NASDAQSRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently completed for what all purposes was a truly banner year for the company. SRAX achieved $46.1 million in bookings for 2021, whilst simultaneously boosting the number of issuers currently subscribing to the Sequire platform to 278 publicly listed corporations. Meanwhile and during the company’s recent annual earnings call on April 4, 2022, SRAX CEO Chris Miglino boosted the company’s full year 2022 revenue guidance to $47 million – $49 million – a further affirmation of SRAX’s positive corporate outlook going forward ( https://ibn.fm/mYKQ0 ).

Shares of Bristol-Myers Squibb Company (NYSEBMY) traded today at $77.84, eclipsing its 12-month high. Approximately 5.2 million shares have changed hands today, as compared to an average 30-day volume of 15.4 million shares.

AutoZone Inc. (NYSEAZO) traded at a new 12-month high today of $2221.57. So far today approximately 62,000 shares have been exchanged, as compared to an average 30-day volume of 204,000 shares.

Duck Creek Technologies Inc. (NASDAQDCT) traded today at a new 12-month high of $69.49. So far today approximately 25.1 million shares have been exchanged, as compared to an average 30-day volume of 918,000 shares.

Lexaria Bioscience (NASDAQLEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The company noted that this data supports similar findings from previous successful studies, all of which support Lexaria’s anticipated move to begin the process of seeking approval for the technology from the U.S. Food and Drug Administration. The company has gathered significant evidence of DehydraTECH-CBD’s ability to reduce blood pressure across a wide variety of situations. The data from the most recent study will be analyzed in order to determine the direction of the company’s upcoming research looking into the efficacy of DehydraTECH-CBD use for the management of elevations in pulmonary arterial pressure under hypoxic conditions, related hypoxemic pathologies and pulmonary hypertension.

In its 2022 State of Protective Intelligence Report, which surveyed security professionals, legal officers, compliance officers, and corporate attorneys at U.S. companies with more than 5,000 employees, the Ontic Center for Protective Intelligence (“OCPI”) noted that 88% of the respondents maintain that their companies are experiencing a substantial uptick in physical threat activity that is expected to grow even further as the year progresses ( https://ibn.fm/LPpq5 ).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), was spotlighted in an episode of the Power Play by the Market Herald. Cybin CEO Doug Drysdale talked with host Dave Jackson about the company’s recent positive results from its CYB004 pharmacokinetic study. The company announced that the study produced positive preclinical data demonstrating that when inhaled, Cybin’s deuterated dimethyltryptamine (“DMT”) molecule indicated advantages, such as a longer duration of action and improved bioavailability, over both IV DMT and inhaled DMT. Power Play interviews with company executives offer investors a quick snapshot of an array of companies, along with a look at each company’s latest news.

A recent Mordor Intelligence article is reporting that the global rare earth elements (“REE”) market has reached an estimated 161,354.65 tons this year, with an expected compound annual growth rate (“CAGR”) of more than 4% between now and 2027 ( https://ibn.fm/6UppN ). That growth could prove beneficial to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company that is also moving faster than any other company to re-establish a domestic REE supply chain.

Deciphera Pharmaceuticals Inc. (NASDAQDCPH) traded today at a new 12-month high of $70.84. Approximately 26.2 million shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares.

AmerisourceBergen Corporation (NYSEABC) traded today at a new 12-month high of $157.76. Approximately 207,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares.

Shares of Walmart Inc. (NYSEWMT) traded today at $153.33, eclipsing its 12-month high. Approximately 2.3 million shares have changed hands today, as compared to an average 30-day volume of 8.1 million shares.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives of the study include extensive subjective evaluations related to throat burn, user experience and more. The design phase of NIC-H22-1 is complete, and test articles are currently being manufactured. Funding NIC-H22-1 with existing capital, the company is optimistic that this larger study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose.

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, hit a critical mineral “trifecta” this month, making commercial shipments of uranium, vanadium and advanced rare earth materials — all in a single week. According to the announcement, the company shipped natural uranium concentrates (“U308”) to the Metropolis Works uranium conversion facility in Metropolis, Illinois; vanadium pentoxide (“V205”) to the Bear Metallurgical Company in Butler, Pennsylvania; and high-purity mixed rare earth element (“REE”) carbonate to the Neo Performance Materials facility in Estonia. “I believe the week of April 4, 2022, will go down as one of the most important weeks in company history,” said Energy Fuels CEO and president Mark Chalmers in the press release. “This week, our vision of Energy Fuels as ‘America’s Critical Mineral and Clean Energy Hub’ tangibly advanced, as our White Mesa Mill in Utah sent three shipments of advanced materials containing a total of 15 critical elements, including the rare earth elements cerium, praseodymium, neodymium, samarium, europium, gadolinium, dysprosium, terbium, holmium, yttrium, erbium, thulium, ytterbium, and lutetium, along with uranium and vanadium, to downstream processing facilities. We sent a shipment of high-purity rare earth carbonate containing 32%–34% NdPr to Silmet in Estonia, where it will be refined and processed into various advanced materials for use in permanent magnets used in electric vehicle motors and wind generation, batteries, electronics, defense applications, and other technologies. We sent a shipment of uranium concentrates to ConverDyn in Illinois for sale to U.S. nuclear utilities for the production of carbon-free nuclear energy, and further adding to Energy Fuels’ industry-leading finished U.S.-origin uranium inventory. And we sent another truckload of vanadium to Bear Met in Pennsylvania for conversion into ferrovanadium for use in high-strength steel and other advanced and specialty alloys. I could not be more proud of what our team is doing at the White Mesa Mill on rare earths.”

Shares of Ovintiv Inc. (NYSEOVV) traded today at $56.31, eclipsing its 12-month high. Approximately 555,000 shares have changed hands today, as compared to an average 30-day volume of 4.9 million shares.

Shares of Matador Resources Company (NYSEMTDR) traded at a new 12-month high today of $57.69. So far today approximately 625,000 shares have been exchanged, as compared to an average 30-day volume of 2.9 million shares.

Shares of Archaea Energy Inc. (NYSELFG) traded at a new 12-month high today of $22.52. This new high was reached on below average trading volume as 112,000 shares traded hands, while the average 30-day volume is approximately 1.5 million shares.

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability,” said Doug Drysdale, chief executive officer of Cybin. “CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.”

GreenBox (NASDAQGBOX), an emerging and rapidly growing fintech company, has completed the System and Organization Controls (“SOC”) 2 Type 2 certification audit. The audit, which started in November 2021, focused on controls relevant to the security trust services category. According to the announcement, SOC 2 Compliance is a recognized auditing standard developed by the American Institute of Certified Public Accountants (“AICPA”) that evaluates a service organization’s systems and determines if specified controls meet relevant trust services categories. Considered the gold standard for establishing trust with customers, the audit also measures the effectiveness of those controls over a specified period of time. “GreenBox customers rely on our customized payment-solutions software as the lifeline for their businesses,” said Greenbox CEO Fredi Nisan in the press release. “This requires the trust and integrity of our security, controls and risk management processes as well as strict adherence to compliance. By completing the SOC 2 type 2 certification, not only do we align ourselves with the industry standards followed by world class organizations, but given our strong growth trajectory, it is indicative of our commitment to protecting both our internal and external constituents while building trust with rigorous control processes and prudent risk management.”

GreenBox (NASDAQGBOX), an emerging and rapidly growing fintech company, has named a new member of its board of directors. The company has appointed transactional lawyer Adele Hogan to the board; Hogan will replace Carl Williams. With more than three decades of experience, Hogan has been involved in an estimated $200 billion of securities, mergers, contracts and closed deals. She is currently a partner at Lucosky Brookman, where she also serves as the cochair of the Corporate, Mergers & Securities Practice Group overseeing mergers and capital markets transactions including IPOs, SPACs, de-SPACs, corporate side of bankruptcies, securities and derivatives. Previously she has been a partner at Hogan Law Associates, where she managed complex mergers, securities offerings, derivatives and financing deals. In addition, she is committed to education, teaching, chairing, and speaking at board associations and Fordham University; she also regularly judges transactional law competitions at Cornell Law School. “Adele is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout her legal career,” said Greenbox chair Ben Errez in the press release. “She is a partner at our securities law firm and has been material to recent acquisitions and securities compliance successes, and will be an important contributor to any M&A and dividend plans. She will be an affiliated board member, bringing the balance in the Board to three affiliated and four independent members. We welcome Adele to the Board and look forward to her contributions as we continue to strengthen and scale our business by integrating and leveraging our recent acquisitions into becoming a truly comprehensive global payment solutions leader.”

Shares of Tractor Supply Company (NASDAQTSCO) traded at a new 12-month high today of $241.48. So far today approximately 166,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares.

W.R. Berkley Corporation (NYSEWRB) traded today at a new 12-month high of $67.00. So far today approximately 441,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.

Lexaria Bioscience (NASDAQLEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for a fee; Altria in turn will evaluate the formulations. The new agreements will continue through March 31, 2023. Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. In addition, the technology has shown the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times as well as decrease time of onset significantly.

Knightscope (NASDAQKSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, has promoted four employees to executive positions. Doris Lam has been named vice president of finance, Jason M Gonzalez has been named senior vice president of client development, Ronald J Gallegos has been named vice president of client experience and Ryan J Fanciullo has been named vice president of operations. According to the announcement, these employees have demonstrated exceptional leadership abilities and have been promoted to capitalize on Knightscope’s current momentum as the company continues focusing on product innovation and sales growth. The new management leads have proven expertise in identifying and executing mission-critical solutions that have driven better operational results, streamlined administrative workflows, accelerated capital formation and increased sales pipeline engagement.

CNS Pharmaceuticals (NASDAQCNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John Climaco, along with opinion leader Samuel A. Goldlust, MD. The focus of the chat will be GBM and the work that CNS Pharmaceuticals is doing to advance Berubicin, its novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier for the treatment of recurrent GBM, one of the most aggressive types of brain cancer. The company is currently conducting a global study evaluating the efficacy and safety of Berubicin in the treatment of GBM. Goldlust is Dr. Goldlust is an investigator in the company’s Berubicin study and a leading neuro-oncologist who currently serves as the Pitkin chair in neuro-oncology and as medical director of the Brain and Spine Institute at John Theurer Cancer Center.

Flora Growth (NASDAQFLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that CEO Luis Merchan will be presenting at the upcoming Benzinga Cannabis Capital Conference. The event is scheduled for April 20–21, 2022, in Miami, Florida. Merchan’s presentation is slated to begin at 3:20 p.m. ET on April 20. In addition to Merchan’s presentation, members of Flora’s management team will be scheduling one-on-one investor meetings throughout the day. The Benzinga Cannabis Capital Conference gathers together more than 1,000 of the top movers and shakers in the cannabis industry and offers an invaluable opportunity for companies operating in the cannabis space to raise money, create partnerships and expand media visibility. The event agenda includes insightful keynote presentations, panel discussions, fireside chats, networking and company presentations as well as investor and celebrity appearances; this year’s event also features a larger exhibit floor and enhanced industry networking opportunities. “We’re looking forward to presenting at the Benzinga Cannabis Capital Conference and sharing valuable insights into our company and the industry as a whole with the attendees,” said Flora Growth CEO Luis Merchan in the press release. “Few events offer a lineup and networking opportunities as Benzinga does.”

The Southern Company (NYSESO) traded at a new 12-month high today of $71.45. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 6.3 million shares.

More than a decade after the Tesla Roadster launched and proved that electric vehicles were commercially viable, the nascent electric vehicle industry is slowly filling up with competition . Gone are the days where the only player in the EV game was Tesla; legacy auto makers and several EV startups have now thrown their hats into the ring in a bid to snag a portion of the lucrative electric vehicle market.

Lexaria Bioscience Corp. (NASDAQLEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake – which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy.”

Shares of General Mills Inc. (NYSEGIS) traded at a new 12-month high today of $70.94. So far today approximately 489,000 shares have been exchanged, as compared to an average 30-day volume of 4.1 million shares.

As a leading innovator in the LiDAR space, Cepton (NASDAQCPTN) has always been committed to becoming the bridge between cutting-edge science and the automotive industry. Autonomous driving and its great enabler – LiDAR technology – are ready to take over mobility space, as the innovative technology makes strides in terms of decreasing costs and improving commercialization potential. Cepton appears determined to be a visible part of that landscape, as it becomes a sponsor and an exclusive LiDAR provider for ten universities in North America gathered in a four-year STEM education program called The AutoDrive Challenge(TM) II ( https://ibn.fm/283iq ).

Shares of Sociedad Quimica y Minera S.A. (NYSESQM) traded today at $85.29, eclipsing its 12-month high. Approximately 141,000 shares have changed hands today, as compared to an average 30-day volume of 1.7 million shares.

Studies have shown that 70% of individuals are converted into repeat paying clients once they attend an experiential marketing event. In addition, 85% of clients note that they are more likely to make a purchase after participating in such events ( https://ibn.fm/K2rQL ).

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that the World Intellectual Property Organization (“WIPO”) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (‘PCT’) patent application no.PCT/EP2021/077057). This further strengthens the company’s long-term intellectual property (“IP”) position of psychedelic-based programs. “The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates,” said Cybin CEO Doug Drysdale. “In addition, our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT.”

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start at 1:10 p.m. ET. The panel discussion, which is titled “Short, Medium, and Long Term Catalysts in Psychedelics,” is scheduled for 3:10 p.m. ET. Archives versions of both events will be available on the company’s investor relations website.

Save Foods (NASDAQSVFD) (FSE: 80W), an agri-food tech company specializing in eco crop protection that helps reduce food waste and ensure food safety, published a letter to its stockholders from CEO David Palach. “We achieved multiple significant milestones in 2021, successfully transitioning Save Foods from a research and development focused organization to a commercial enterprise, fueled by the transformational May 2021 listing of our common stock on the Nasdaq Capital Market through an initial public offering that raised gross proceeds of $12 million. Even though we were an R&D focused company for much of 2021, and despite ongoing travel impacts related to COVID-19, I am pleased to report our team delivered 89% revenue growth over 2020,” Palach states in the letter. “With the capital in place to begin executing our vision in earnest, we embarked on an ambitious agenda in the second half of the year to accelerate our penetration into key markets and fortify our foundation for long-term growth. As part of that foundation, we completed the build-out of Save Foods Ltd.’s new headquarters and R&D center in Neve Yarak, Israel, providing ample room for our growing team to perform as we scale our operations in the fiscal quarters ahead. This facility completements our growing global network of agents in Mexico, Turkey, Egypt, South Africa, and Peru.”

Cepton (NASDAQCPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the BofA Securities Global Automotive Summit on April 13, 2022. According to the announcement, Cepton is scheduled to present at 1:20 p.m. ET on Wednesday, April 13. Interested parties may visit https://ibn.fm/Q4V6i to register to view a live webcast of the presentation. The registration link and Cepton’s investor presentation can also be found at https://investors.cepton.com .

Flora Growth (NASDAQFLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, and its newly acquired brand, Just CBD, have partnered with distribution company OTG Management to carry its CBD products in airports. The brand will initially be available in Houston’s George Bush Intercontinental/Houston Airport and Washington, DC’s Ronald Reagan Washington National Airport, with plans to expand distribution soon. The first products ordered by OTG Management, which is a leading operator of airport restaurants and retail storefronts in airports across the United States, were JustCBD’s night-time gummies and regular gummies. “Airport retail sales represent a billion-dollar business, and we’re proud to have our JustCBD brand be accepted as one of the first world-class CBD lines of product to be distributed in US airports,” said Flora CEO Luis Merchan in the press release. “As Flora continues to execute on its strategy to build a global house of brands and become one of the world’s largest distributors of cannabis derivatives, availability of JustCBD products in airports across the US is a meaningful step forward in our growth. We hope to expand our relationship with OTG as we explore the opportunity their significant footprint represents across our house of brands.”

GreenBox (NASDAQGBOX), an emerging and rapidly growing fintech company, has announced an acquisition that will bring significant processing volume portfolio in-house. The asset purchase agreement with Sky Financial & Intelligence, will enhance GBOX margins and create additional revenue-generating opportunities for the company. In the transaction, GreenBox purchased a portfolio of merchant accounts for $16 million in cash and 500,000 restricted common shares. According to the announcement, one of the portfolios has been integrated with GreenBox’s technology and ecosystem for more than a year. During that time, the portfolio grew to more than $1 billion in total processing volume and played a key role in GBOX’s success last year. “The acquisition of the substantial Sky portfolios is yet another stride forward for us and accomplishes two very important things,” said GreenBox chair Ben Errez in the press release. “By bringing a large merchant account portfolio in-house, we eliminate the cost previously incurred from commissions and amplify our margin profile. Second, it allows GreenBox to own these customer relationships, securing a considerable portion of our processing volume base with the bonus of being able to offer additional revenue generating solutions. Lastly, Sky’s processing volume played a vital role for us in meeting the fundamental hurdle requirements in our convertible note.”

SRAX (NASDAQSRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has announced that the Sequire Cannabis & Psychedelic Conference is scheduled for April 20, 2022, from 9 a.m. to 4 p.m. ET. The conference will be held via SRAX’s Sequire Virtual Events. The one-day virtual event is expected to draw significant numbers; almost 9 million active small cap investors have been invited to attend. The event agenda keynote addresses by several well-known names in the industry and also includes some 25 cannabis and psychedelic companies offering 25-minute presentations. “This our second annual Sequire Cannabis & Psychedelic Conference,” said SRAX vice president of community and events Morgan Fogg in the press release. “We are delighted by the public companies joining the program this year and have some stimulating speakers rounding out our keynotes and panels. We recently launched new 1:1 feature updates to the Sequire Virtual Events platform, so we are looking forward to having our audience experience that too.”

Knightscope, Inc. (NASDAQKSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, yesterday announced that it entered into a $100 million common stock purchase agreement with B. Riley Principal Capital. Knightscope, which is celebrating its 9 th anniversary, announced that the committed equity facility provides the company with the right to sell and issue up to $100 million of its Class A common stock over a period of 24 months to B. Riley. The company can do so at its discretion and without obligation, although any transactions will be subject to some limitations and conditions.

Cepton (NASDAQCPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced the appointment of Hull Xu, the company’s VP of finance and strategy, to the position of chief financial officer. Effective immediately, Xu succeeds Dr. Winston Fu, Ph.D., who will remain with the company as an advisor on strategic projects. Dr. Fu will also remain on the board of directors and become vice chairman. “Hull has demonstrated tremendous leadership and experience in finance and strategic matters since he joined Cepton,” said Dr. Jun Pei, Cepton’s co-founder, chairman and CEO. “We look forward to Hull’s continued contribution as he takes on the expanded role of CFO. We also thank Winston for his many contributions and look forward to continuing our work together on strategic projects. We will benefit from Winston’s guidance and experience as a member of Cepton’s board.”

CNS Pharmaceuticals (NASDAQCNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received key approval for a planned study. The approval came from Swissmedic, the Swiss agency for therapeutic products. CNSP can now move forward with its potentially pivotal study of its novel anthracycline, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”); the company has already received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland, for the study. According to the announcement, execution of global patient enrollment is moving forward.”With the necessary regulatory approvals in Switzerland now in place, our team is diligently working to bring clinical sites online and quickly and efficiently drive patient enrollment in this potentially pivotal study,” said CNS Pharmaceuticals CEO John Climaco in the press release. “We are sincerely grateful to the Swiss Competent Authority and Ethics Committee and their positive feedback on what we continue to believe is an incredibly important clinical program. We are laser focused on advancing Berubicin to unlock its greatest potential as a possible critical treatment option for this devastating disease. As long as the unmet medical need in GBM remains, we will continue our fight to bring hope to patients and families.”

GreenBox (NASDAQGBOX), an emerging and rapidly growing fintech company, has completed its acquisition of Transact Europe Holdings (“TEU”). According to the company, the $28 million purchase price was substantiated by the value of Transact Europe’s business volume, strategic licenses, systems and personnel. An EU-regulated electronic money institution, TEU is headquartered in Sofia, Bulgaria, and holds an array of valuable licenses, including principal level membership of Visa, worldwide membership of MasterCard and principal membership of China UnionPay. “This acquisition is a momentous triumph for us, representing the most significant asset to date for GreenBox, allowing us to propel forward as a significant player in the European and global marketplace,” said GreenBox chair Ben Errez in the press release. “GreenBox and TEU are a natural complement to each other with TEU’s licenses and infrastructure combined with GreenBox’s suite of customized blockchain payment solutions, global strategy and technology creating a powerful synergy that we believe will quickly scale in the European market in which noncash payments account for over 100 billion transactions and exceed 160 trillion euros per year. Furthermore, our combined infrastructure paves the way for expansion into other digital payments markets and countries around the world. As a result, we expect to see momentous gains in processing volume leading to stronger revenue contribution and long-term sustainable value our shareholders expect.”

Xcel Energy Inc. (NASDAQXEL) traded at a new 12-month high today of $74.02. This new high was reached on below average trading volume as 251,000 shares traded hands, while the average 30-day volume is approximately 3.2 million shares.

CNS Pharmaceuticals (NASDAQCNSP), a clinical-stage biotech company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently participated in the 2022 Virtual Growth Conference presented by the Maxim Group LLC and hosted by M-Vest from March 28-30. CEO of CNS, John Climaco, represented the company, sharing the corporate presentation and participating in a fireside chat that was moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group. The CNS corporate presentation was made available on-demand to those attending the virtual summit.

Mullen Automotive (NASDAQMULN), an emerging electric vehicle (“EV”) manufacturer, has promoted John Taylor to the role of senior vice president of Global Manufacturing and Strategic Planning; Taylor had been serving as vice president of manufacturing for Mullen since January. Throughout his career, Taylor has gained impressive experience, including the management of several plant start-ups and more than 12 vehicle launches in the United States and around the world. Taylor began his career with General Motors where he served as launch manager, operations manager, and machine and equipment manager, was involved with 11 major automotive vehicle launches. Taylor joined Tesla in 2010 as one of the company’s first 50 employees, leading the advanced manufacturing engineering group. Taylor played a key role in the opening of Tesla’s Fremont facility, overseeing manufacturing operations for the Tesla Model S and managing architecture for future EV projects. “John brings a wealth of experience in the EV manufacturing space. He plays a critical role in the ongoing setup and expansion of Mullen’s Advanced Manufacturing and Engineering Center in Tunica, Mississippi,” said Mullen Automotive CEO and chair David Michery in the press release. “John’s international manufacturing experience will come into play as he strategizes and evaluates Mullen’s other domestic and international manufacturing opportunities.”

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that Adelia Therapeutics, a wholly controlled subsidiary of Cybin, has achieved the milestone identified as Year 1, Q2 (iv) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020. The transaction agreement was among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “We are extremely pleased with the rate and speed in which our team has been able to achieve these milestones that support our pipeline of novel psychedelic-based therapeutic candidates,” said Cybin CEO Doug Drysdale. “These advancements are important catalysts for our clinical development path as we prepare these programs for our planned clinical trials in 2022.”

Nemaura Medical (NASDAQNMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report trauma and bruising in addition to changes to the skin surface. In contrast, Nemaura Medical’s sugarBEAT(R) and proBEAT(TM) continuous glucose monitors (“CGMs”) sit on the surface of the skin, are easy to apply, and can be worn comfortably without the need for extended periods of wear, providing real-time insights into a person’s state of metabolic health, dietary guidance and exercise recommendations with the aim of improved long-term health and wellness,” a recent article reads. “At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant health care needs for large patient populations,” said Nemaura CEO Dr. Faz Chowdhury. “We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.”

Flora Growth (NASDAQFLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that Colombia has completed its required regulations to allow cannabis companies operating in the country, including Flora Growth, to export THC and CBD dried flower. The country passed Resolution 539 on April 1, 2022, which is a regulatory checklist for companies; the resolution includes export quotas. The export steps included in the resolution outline adjustments to Flora’s approved 43.6-ton quota, which means the addition of dried flower can be included with FLGC’s existing purchase agreements from countries including Germany, Israel, Australia, South Africa, Portugal and Malta. According to the company, the updated regulation also includes a requirement for genetics registrations for all high-THC cultivars. The company also noted that its quota already permitted the export of derivative products produced at its cultivation facility. “Flora applauds the recent announcement by the Colombian government as we have been working diligently to have all the necessary approvals and capabilities available to produce high THC flower, including multiple cannabis strains with THC levels over 20 percent,” said Flora Growth’s chief commercial officer Jason Warnock in the press release. “This resolution also clears the path to export dried CBD flower to markets including the United States where Flora already sells hundreds of CBD products via owned brands like JustCBD, MIND, and Mambe.”

Northern Oil and Gas Inc. (NYSENOG) traded at a new 12-month high today of $29.21. Approximately 82,000 shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares.

Lottery.com (NASDAQLTRY), a leading technology company that is transforming how, where and when the lottery is played, is reporting its fourth-quarter and full-year 2021 revenue for the period ending Dec. 31, 2021. Q4 revenue totaled $21.5 million, an increase of $18.2 million over the previous year, with full-year revenue of $68.5 million, an increase of $61 million over 2020 numbers. The company also reported full-year 2021 pro forma revenue of $70.5 million, including acquired interest in Mexican entities, with full-year 2021 net loss of $9.3 million and adjusted EBITDA of $31.1 million. Corporate highlights include the company’s successful completion of its business combination with Trident Acquisitions Corp. with growth coming from the sale of LotteryLink credits to a LotteryLink affiliate; the company also sold LotteryLink credits for marketing materials, product development and $3 million in prepaid advertising credits. “In the fourth quarter and throughout 2021, we demonstrated our ability to execute our strategic growth initiatives across the business to generate strong revenue growth and gross profit,” said Lottery.com cofounder and CEO Tony DiMatteo in the press release. “B2C sales increased compared to the prior year period, despite no digital marketing spending. LotteryLink, our affiliate program, expanded and generated multiple revenue streams. I am extremely proud of our team achieving these accomplishments while successfully closing the business combination and taking our company public. We entered 2022 with positive momentum and continued focus on executing our strategic growth plan. Fueled by approximately $43 million of proceeds from our business combination and $30 million received from the sale of LotteryLink credits, we are investing in initiatives to drive growth.”

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that the first visit has been conducted in a Cybin-sponsored feasibility study. The study will focus on evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By deploying the innovative Flow technology, this is the first time any company has had the ability to collect and quantify longitudinal brain activity before, during and after a psychedelic experience. We are specifically encouraged by this scientific advancement as it has the potential for Cybin to collect real-time quantitative data for our promising psychedelic-based therapies. These data will support the company’s leading research position as we move our important treatment options through regulatory discussions and late-stage clinical development.”

GreenBox (NASDAQGBOX), an emerging and rapidly growing fintech company, is reporting financial results for the fourth quarter and full year for the period ended Dec. 31, 2021. Report highlights include record revenue for the company, which totaled $26.3 million for the year; an increase of $17.8 million or 208.6% over the $8.5 million reported in 2020; a processing volume increase of nearly tenfold to an estimated $2 billion; and a key licensing partnership with Cross River, a respected technology-driven infrastructure provider designed to initiate banking as a service offering, which will allow the company to significantly expand its reach to potential customers, creating new channels for revenue growth. In addition, the company unveiled both a new ACH bulk-processing channel with client commitments topping $50 million per month and a global initiative to broaden GBOX brand awareness by working with award-winning international agency INNOCEAN. The report also noted that the company had strengthened its balance sheet, gained growth capital with the issuance of a $100 million convertible debt financing and accelerated its share repurchase program by approving an additional $10 million for repurchase. “2021 was highlighted by the rapid expansion of our payment processing footprint and a record approximately $2 billion in processing volume,” said GreenBox POS CEO Fredi Nisan in the press release. “This represents growth of nearly 10x over 2020, a milestone achievement that demonstrates the scalability of our technology, our market share growth, our ability to remain compliant, and the quality of our sales team and overall ecosystem for our growing client roster. This KPI translated into record company revenue during 2021 of $26.3 million, representing tremendous growth of over 209% when compared to 2020’s full year revenue. . . . Looking forward, we remain highly focused on the pursuit of our objectives to build compliant, cutting edge blockchain ledger tokenized payment solutions for the diverse, evolving and dynamic global market. Considering our global expansion plans and potential acquisitions, we expect to increase our processing volume in 2022 to between $4 to $5 billion.”

Shares of Waste Connections Inc. (NYSEWCN) traded today at $140.93, eclipsing its 12-month high. This new high was reached on below average trading volume as 138,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares.

SRAX (NASDAQSRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that it will host the 2022 LD Micro Invitational. The prominent three-day investor conference is slated to take place on June 7-9, 2022, at the Four Seasons Hotel Westlake Village, California. Approximately 200 companies from all over the world will showcase what makes them truly special at the event, each presenting for 25 minutes and finalizing their exhibition with private meetings. SRAX will soon release the link to register for virtual and physical components of the event. Chris Lahiji, founder of LD Micro, host to the most influential conferences in the small and microcap world, notes that the Main Event last October was a “great success that restored humanity within our industry. People could finally see each other and connect again in person. As a result, the upcoming Invitational was the fastest sell-out in our history.”

Knightscope (NASDAQKSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced its spring 2022 Robot Roadshow schedule. Designed to be an engaging experiential event that allows Knightscope to connect with potential clients and showcase its proprietary crime-fighting robots, the Robot Roadshow will begin on April 12, 2022, and will tour 10 states, including Minnesota, Wisconsin, Illinois, Indiana and Ohio, with 35 scheduled stops. The roadshow will also be in Washington, D.C. during National Police Week. Creative marketing events such as the Robot Roadshow allow KSCP, a public safety innovator, to educate existing and potential clients and others about its Autonomous Security Robots (“ASRs”). Each roadshow landing is attended virtually by a Knightscope expert, and visitors can interact directly with ASRs as well as view the Knightscope Security Operations Center (“KSOC”) user interface in action. Knightscope is planning to continue the Robot Roadshow throughout the year, hitting as many major cities as possible.

Lexaria Bioscience Corp. (NASDAQLEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the award of the 24th patent, Lexaria already had a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.”

Virtu Financial Inc. (NASDAQVIRT) traded today at a new 12-month high of $38.38. Approximately 420,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares.

Public Service Enterprise Group Inc. (NYSEPEG) traded today at a new 12-month high of $69.33. This new high was reached on below average trading volume as 162,000 shares traded hands, while the average 30-day volume is approximately 2.7 million shares.

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a significant milestone toward advancing this program into first-in-human clinical development and brings us one step closer to progressing CYB003 as a best-in-class treatment candidate for mental illness and addiction,” said Cybin CEO Doug Drysdale. “We plan to focus the Phase 1/2a trial in the United States. We believe this will allow us to escalate the study through early-stage clinical development and into a potential broader Phase 2b trial, while concurrently collecting a large amount of data to support late-stage studies.”

SRAX (NASDAQSRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has announced an upcoming conference call to discuss its full year and fourth quarter 2021 results; the call is scheduled for Monday, April 4, 2022, at 4:30 p.m. ET. SRAX founder and CEO Christopher Miglino will be joined with SRAX chief financial officer Michael Malone during the call; the pair will provide a summary of its fourth-quarter and full-year 2021 report. The call will also include a question-and-answer session. Interested individuals can dial 346-248-7799 then use meeting ID 92478894626 and pass code 223670 to access the call. The call will be available on the company website for 90 days following the call.

Knightscope (NASDAQKSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has deployed another of its proprietary K5 Autonomous Security Robots (“ASRs”) in California. The white and red K5 ASR is patrolling a Silicon Valley commercial real estate (“CRE”) twin-tower office complex. The company noted that today’s CRE tenants are looking for the latest security when they sign a lease package. Commercial property managers need security strategies designed to provide protection against the unique nature of today’s threats while still providing convenience and flexibility; Knightscope shines in offering solutions to these demands. The company’s smarter security strategy is efficient, fast and improves the overall security posture with less investment.

Flora Growth (NASDAQFLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, will be participating in the Plant Medicine Week conference, which is scheduled to be held April 5–8, 2022, in Malta. Flora Growth chair and CEO Luis Merchan is the keynote speaker at the four-day event. Merchan’s presentation, titled “Malta — The Gateway to South American and European Cannabis Relations,” is slated to start at 2:30 CET and will focus on the opportunity presented by Malta’s standpoint on cannabis as well as the cost advantages of South American cultivation and the broader European opportunity. The Plant Medicine Week conference in Malta is designed to gather together industry professionals and attendees and provide them with a diverse and inspiring perspective on the latest advances in the cannabis and psychedelics industries; the event agenda features a mix of exhibitions, presentations, discussions and Q&A sessions. In addition to delivering the keynote address, Merchan will be available for meetings with interested media and others who may want to hear about the cannabis opportunity in the European Union, the industry’s need for more sustainable cultivation practices and Flora’s growth strategy. “I’m honored to be keynote speaker at the Plant Medicine Week conference this year in Malta,” said Flora Growth CEO Luis Merchan in the press release. “I look forward to sharing our expertise as a global cultivator and distributor in the international cannabis space and continuing to foster our relationship with the country of Malta, a leader in Europe’s cannabis trade.”

Mullen Automotive (NASDAQMULN), an emerging electric vehicle (“EV”) manufacturer, expects to report more than $65 million in cash and cash equivalents when it files Form 10Q for second quarter, the period ending March 31, 2022. The company has made significant progress and taken milestone steps during the quarter, including beginning trading on the Nasdaq Capital Markets LLC under the stock ticker symbol MULN. Mullen has also unveiled two versions of its Mullen FIVE show cars and purchased a vehicle manufacturing facility in Tunica, Mississippi. In addition, the company has entered into several key partnerships, with the expectation that these strategic collaborations will play a critical role in bringing its EVs to market quickly. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, the Mullen ONE EV Fleet Vans and the DragonFLY Sports Car. “We’ve made tremendous progress in key areas over the past three months,” said Mullen Automotive CEO and chair David Michery in the press release. “With the financing we received, we now have more than enough capital to execute on our commitments for 2022, including the start of the Mullen FIVE EV Crossover program and continued development on the Mullen ONE EV Cargo Van program. The company’s balance sheet is the strongest it has ever been in our history.”

Save Foods (NASDAQSVFD) (FSE: 80W), an agri-food tech company specializing in eco crop protection that helps reduce food waste and ensure food safety, today announced that it will present its green products and treatments that have proven successful tools in fighting food waste of fresh produce all along the supply chain. According to the update, Save Foods will present in hall 5.2, booth number D-12e at the Fruit Logistica Trade Fair in Berlin from April 5-7, 2022. Companies interested in finding out more about Save Foods’ products should visit https://ibn.fm/pRHa8 to pre-book a meeting with the team. “Fruit Logistica is a global exhibition featuring the entire spectrum of the fresh fruit and vegetable sectors,” said Dan Sztybel, CEO of Save Foods’ Israeli subsidiary. “It is a great opportunity to share our latest developments and connect with other produce industry leaders in our fight against food waste.”

Cepton (NASDAQCPTN) recently entered into a partnership with Fibre Based Integrations, an established fiber optics systems house, to develop a lidar-based vehicle detection system aimed at assisting the creation of smart transportation infrastructure in Cape Town, South Africa. “The use of Cepton’s innovative lidar technology will allow the system to provide authorities with analytics designed to improve traffic flow and safety for motorists and pedestrians alike,” reads a recent article. The autonomous vehicle sector has widely acclaimed lidar technology as a key sensor technology; it has a higher spatial resolution, which allows it to perform better than cameras and radars in various weather and lighting conditions. “Josh Goosen, system engineer at Fibre Based Integrations, remarked in relation to the Cepton partnership, ‘The reason we chose to deploy lidars in our vehicle detection and classification systems is their superior accuracy. We found Cepton lidars to be the best performing and most accurate compared with others we tested, and this has unlocked new possibilities for implementing our smart city solutions with the City of Cape Town.’”